Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment.

Moshe C OrnsteinLisa C RosenblattXin YinViviana Del TejoSarah B GuttenplanFlavia EjzykowiczKathleen BeusterienOliver WilldeMauri S MackieGrace Skiles Marc DeCongelio

Published in: Patient preference and adherence (2024)

In this study, patients highlighted that improving survival time was the most important and that QoL is also an important consideration. Discussions during treatment decision-making may benefit from broader conversations around treatment characteristics, including impacts on QoL and convenience of the regimen.

Keyphrases

decision making
renal cell carcinoma
end stage renal disease
ejection fraction
prognostic factors
combination therapy
replacement therapy
patient reported